Dose escalation for secondary loss of response in inflammatory bowel disease: 3‐year outcomes and treatment persistence
Internal Medicine Journal · 16.08.2026
DOI: 10.1111/imj.70604 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, online erschienen am 16.08.2026. Verfasst von Faris Gondal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Royal Melbourne Hospital, Melbourne, Victoria, Australia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
Dose escalation of biologic therapies is commonly used to manage secondary loss of response in inflammatory bowel disease, although long‐term real‐world outcomes remain limited.
Aims
To evaluate long‐term clinical outcomes and treatment persistence following biologic dose escalation for secondary loss of response in inflammatory bowel disease.
Methods
We conducted a retrospective cohort study of patients with inflammatory bowel disease who underwent dose escalation of infliximab, adalimumab or vedolizumab at a tertiary referral centre between 2018 and 2024. Outcomes included clinical disease activity scores, biochemical markers and treatment persistence, assessed at 3–12 months and annually up to 36 months following escalation.
Results
A total of 155 patients were included (median age 31 years; 46% female), of whom 76% had Crohn's disease. A total of 89 patients received infliximab, 48 adalimumab and 18 vedolizumab. Dose escalation was undertaken for secondary loss of response in 68% and low drug concentrations in 42%. Infliximab escalation was associated with improvement in disease activity scores at 3 months, sustained to 36 months, with reductions in C‐reactive protein across follow‐up. Adalimumab escalation improved Harvey–Bradshaw Index at 3, 12 and 24 months, with reduction in faecal calprotectin at 3 months. Vedolizumab escalation improved Simple Clinical Colitis Activity Index at 3 months only. Treatment persistence at 36 months was 58% for infliximab, 65% for adalimumab and 73% for vedolizumab. Nine patients experienced minor adverse events.
Conclusions
Biologic dose escalation was associated with improvement in disease activity and modest treatment persistence following secondary loss of response in inflammatory bowel disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
- Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
ORCID-Profile: Faris Gondal, Omar Salehi, Joshua Haron Abasszade, Finlay Macrae, Jonathan P Segal
Zitieren
APA
Gondal, F., Terlato, M., Salehi, O., Pillay, L., Rentsch, C., Dimovski, S., Abasszade, J. H., Macrae, F., & Segal, J. P. (2026). Dose escalation for secondary loss of response in inflammatory bowel disease: 3‐year outcomes and treatment persistence. Internal Medicine Journal. https://doi.org/10.1111/imj.70604
Vancouver
Gondal F, Terlato M, Salehi O, Pillay L, Rentsch C, Dimovski S, et al. Dose escalation for secondary loss of response in inflammatory bowel disease: 3‐year outcomes and treatment persistence. Internal Medicine Journal. 2026. doi:10.1111/imj.70604
BibTeX
@article{Gondal2026,
author = {Gondal, Faris and Terlato, Maddison and Salehi, Omar and Pillay, Leshni and Rentsch, Clarissa and Dimovski, Stephanie and Abasszade, Joshua Haron and Macrae, Finlay and Segal, Jonathan P},
title = {Dose escalation for secondary loss of response in inflammatory bowel disease: 3‐year outcomes and treatment persistence},
journal = {Internal Medicine Journal},
year = {2026},
doi = {10.1111/imj.70604}
}
EUVIMED